Introduction {#sec1-1}
============

Extended spectrum β-lactamases (ESBLs) are enzymes produced by a variety of Gram-negative bacteria which confer an increased resistance to commonly used antibiotics, such as the penicillins and the cephalosporins \[[@ref1]\]. These ESBLs are mostly plasmid mediated and efficiently hydrolyze oxyimino cephalosporins (ceftazidime, cefotaxime, and ceftriaxone) and monobactams. They are inhibited by β-lactamase inhibitors such as clavulanate, sulbactam, and tazobactam \[[@ref2]\]. Plasmids coding for ESBLs may also carry additional β-lactamase genes as well as genes conferring resistance to other antimicrobial classes \[[@ref3], [@ref4]\]. This can limit the chemotherapeutic options for ESBL-producing pathogens and facilitates inter-species and intra-species dissemination of ESBLs \[[@ref5]\]. As such, they are a worrying global public health issue as infections caused by such enzyme-producing organisms are associated with a higher morbidity and mortality with greater fiscal burden coupled with increasing prevalence rates worldwide and an ever diminishing supply in the antibiotic armamentarium, and these enzymes represent a clear and present danger to public health \[[@ref1]\].

ESBLs have been found mainly in *Enterobacteriaceae*, particularly *Klebsiella* species and *Escherichia coli*, but have also been reported in other genera, such as *Citrobacter, Enterobacter, Morganella, Proteus, Providencia, Salmonella*, and *Serratia* and in *Pseudomonaceae.* In Nigeria urinary tract infection (UTI) is one of the most common diseases that make people seek medical attention with the majority of infections caused by *Enterobacteriaceae* and *Pseudomonaceae* \[[@ref6]\]. Reports of multidrug-resistant isolates have increased during the last decade, probably as a result of the extensive use of broad-spectrum antibiotics. Cefotaximase-Munich (CTX-M)-type ESBLs have emerged among *E. coli* and *Klebsiella pneumoniae* and are now commonly isolated from UTIs, and often, these enzymes are carried by strains with a multidrug resistance phenotype. Multidrug resistance expressed by CTX-M-producing isolates from the community is often associated with the presence of multiple ESBLs genes, as well as aminoglycoside and quinolone resistance genes, thereby limiting the choice of effective antimicrobial drugs. Studies on the causative agents of UTIs in Nigeria and their susceptibility to antimicrobials are lacking; particularly, there is paucity of information on the characterization of ESBLs genes in *Enterobacteriaceae* and *Pseudomonaceae* from patients with UTIs. Therefore, the study aimed to determine the presence and characteristics of extended spectrum β-lactamases in commonly isolated uropathogenic GNB in Nigeria.

Materials and Methods {#sec1-2}
=====================

**Bacterial Isolates and Study Sites.** A total of 50 non-duplicate unbiased GNB isolates consisting of *E. coli*, 19; *K. pneumoniae*, 21; and *Pseudomonas aeruginosa*, 10 were obtained from three tertiary hospitals in Nigeria. The distribution of the isolates from the hospitals is as follows: hospital I, 24; hospital II, 16; and hospital III, 10; these hospitals are located at Ibadan, Ogbomoso, and Osogbo, respectively, in South West Nigeria. Each isolate was obtained from a patient with significant bacteriuria diagnosed of varying specific and general UTIs ranging from pyelonephritis, cystitis, prostatitis, and so on. All isolates were speciated using Analytical Profile Index (API) 20E strips (BioMerieux, France) and conventional biochemical tests. The study was carried out at the Molecular Biology Laboratory of Department of Biomedical Science, Ladoke Akintola University of Technology, Ogbomoso, Osogbo campus.

**Antibiotic Susceptibility Testing.** The antibiotic susceptibility patterns of all the isolates to a panel of antibiotics were determined by the disk diffusion method (disks from Oxoid, UK) using Mueller-Hinton agar according to Clinical Laboratory Standards Institute (CLSI) guidelines \[[@ref7]\]. Resistant isolates were further selected for susceptibility testing to β-lactam drugs such as ceftriaxone, ceftazidime or Amoxycillin-clavulanic acid using the agar doubling dilution method \[[@ref8]\]. All runs included the control organisms such as *E. coli* (NCTC 10418) for *Enterobacteriaceae* and *P. aeruginosa* (NCTC 10662) for *Pseudomonas* species.

**Phenotypic Detection of β-lactamases.** Broth cultures of each test strain as well as ampicillin-resistant *E. coli* strain NCTC 10418 (carrying pUC18) were incubated overnight in 5 ml of Luria--Bertani broth. Then, 200 μl of the resulting overnight culture was transferred into the wells of a microtiter tray, and sterile broth was included as a negative control. Then, 10 μl of nitrocefin solution (Fisher Scientific, Loughborough, UK) prepared according to the manufacturer\'s instructions was added to each well. β-Lactamase production was inferred when the broth turned red within 30 min of addition of nitrocefin as directed by the manufacturer.

**Detection of Extended-spectrum β-lactamases by the Double-disk Diffusion Test (DDDT).** Suspensions of each test strain were prepared in sterile water to give an inoculum equivalent to a 0.5 McFarland standard before being used to inoculate the surface of Mueller-Hinton agar plates \[[@ref8]\]. ESBL-positive *K. pneumoniae* ATCC 700603 and ESBL negative *E. coli* ATCC 25922 control strains were used in these experiments. A 30-μg ceftazidime disk (the best indicator for Temoneira (TEM)- and SHV-derived ESBLs) was placed on the left of each plate and a 30-μg cefotaxime disk (the best indicator for CTX-M types) was placed on the right; an AMC (20/10 μg) (Oxoid Ltd., Basingstoke, UK) was placed in the center between the other disks. The disks were placed 25--30 mm apart, center-to-center. Following overnight incubation in air at 37 °C, ESBL production was inferred when the zone of inhibition around the ceftazidime and cefotaxime disks was expanded by ≥5 mm by the presence of clavulanic acid.

**Amplification of ESBL Genes.** Polymerase chain reaction (PCR) was used to detect genes encoding resistance to β-lactams (*bla*OXA, *bla*SHV, *bla*CTX-M, *bla*VEB, *bla*PER, *bla*OXA-10, *bla*OXA-48, *bla*KPC, *bla*NDM, *bla*GES, *bla*VIM) as previously described ([Table 1](#table001){ref-type="table"}) \[[@ref9], [@ref10]\]. Amplimers resulting from these PCR reactions were sequenced at Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK to confirm the identity and specific variant of each gene identified and sequences were aligned to known reference sequences using ClustalW (<http://www.ebi.ac.uk/Tools/msa/clustalw2/help/index.html>).

RAPD PCR Typing. The epidemiological relationships between multiple strains of *E. coli, K. pneumoniae*, and *P. aeruginosa* carrying ESBLs were analyzed according to species by randomly amplified polymorphic DNA (RAPD). The primers sequence and PCR running conditions used were according to Vogel *et al.* \[[@ref11]\] modified to use 1 μl of 100 μmol of primers at a final concentration of 0.02 μmol \[[@ref6]\]. The experiment was repeated twice for each species to ensure reproducibility. DNA fingerprints were compared by visual inspection to assign similar banding patterns to the same RAPD type.

**Statistics Analysis.** Data were analyzed using the statistical package within Microsoft Excel. χ^[@ref2]^ was used to determine the association between distribution of ESBL genes and hospitals. In this case, *p* value less than 0.05 was considered to be significant.

Results {#sec1-3}
=======

**Antimicrobial Susceptibility Testing.** A total of 50 clinical isolates of GNB were obtained from three tertiary hospitals in South West Nigeria. These isolates were obtained from patients suffering from UTIs with significant bacteriuria. API and other biochemical tests characterized these GNB to be *E. coli*, K. *pneumoniae*, and *P. aeruginosa.* The results of antimicrobial susceptibility testing showed that colistin was more susceptible at 78% followed by imipenem, 72%. The cephalosporin class of antimicrobial agent such as ceftriaxone recorded 32% with ceftazidime having 30%. Surprisingly, tigecycline had the least susceptibility of 0% followed by ciprofloxacin 2% ([Table 2](#table002){ref-type="table"}). The minimum inhibitory concentrations (MICs) of ceftriaxone, ceftazidime, and amoxycillin-clavulanic acid showed that there were no differences between the MIC~50~ and MIC~90~ of all the isolates. MIC~50~ and MIC~90~ of *K. pneumoniae, E. coli*, and *P. aeruginosa* were \>128 μg/ml having 100% resistance in some cases ([Table 3](#table003){ref-type="table"}). These results indicate that the uropathogenic isolates were highly resistant strains.

**Detection of Extended Spectrum β-lactamases.** Twenty-one (42%) of the isolates were ESBL producers ([Table 4](#table004){ref-type="table"}). Polymerase chain reactions and sequencing identified varying ESBLs encoding genes for 24 isolates (48.0%). CTX-M-15 was the dominant gene with 20/24 of the isolates positive at 83.3%; multiple genes (2 to 6 ESBL genes) were found in 20 of the isolates. The isolates encoded other genes such as CTX-M-14, 33.3%; SHV variants, 58.3% (all SHV variants were encoded as a multiple gene); oxacillinase (OXA) variants, 70.8%; OXA-10, 29.2%; and Vietnamese extended β-lactamase (VEB) 1, 25.0%. Of these, 11/19 (57.9%) E. coli, 11/21 (52.4%) *K. pneumoniae*, and 2/10 (20%) *P. aeruginosa* carried these respective ESBL genes. However, none of the isolates was positive for any of the carbapenemase genes tested in this study. The ESBL genes were found in the three hospitals and the isolates in varying proportions including the clinical diagnosis. However, no association was found between hospitals and distribution of ESBL genes (*X*^[@ref2]^ = 1.32; *p* = 0.85; *p* \> 0.05).

**Typing of Isolates.** The degree of clonality among the resistant isolates revealed high diversity among all the isolates tested with no identical RAPD or banding patterns observed except lanes 3 and 5 ([Figure 1](#fig001){ref-type="fig"}). This suggests that the resistance is underpinned by spread of resistance genes and not expansion of a dominant clone(s).

Discussion {#sec1-4}
==========

CTX-M-15 was the dominant ESBL gene, followed by OXA, SHV, CTX-M-14, OXA-10, and VEB-1 in frequent order. This is consistent with the present antimicrobial resistance situation among *Enterobacteriaceae* where the CTX-M family has replaced TEM and SHV types and became the dominant ESBL in most parts of the world including Nigeria, where they are prevalent both in the hospital and community settings \[[@ref6], [@ref12], [@ref13]\]. In Morocco, CTX-M was detected in 6 out of 7 ESBL-producing E. coli with a predominance of CTX-M-15 (6/6) \[[@ref14]\], while in Cameroon all the ESBL-*E. coli* strains isolated from stool samples of women with UTIs contained group 1 CTX-M enzymes \[[@ref15]\]. Similarly, CTX-M-15 dominated ESBLs in *Enterobacteriaceae* isolated from environmental samples in a hospital in Tunisia \[[@ref16]\]. The high distribution of CTX-M-15 type ESBLs among these isolates explains the high rate of resistance to cephalosporin such as cefotaxime, ceftriaxone, and ceftazidime in our study.

CTX-M-15 co-existed with either OXA-10 or VEB-1 in all the isolates of *E. coli, Klebsiella* species, and *P. aeruginosa.* VEB-1 was first described in an *E. coli* isolate from Vietnam in 1998 \[[@ref17]\]. Ever since, it has been reported from various parts of the world in different species of Enterobacteriaceae \[[@ref18]\], including Nigeria where Aibinu *et al.* reported the emergence of OXA-10, VEB-1, and Cephamycins (CMY) β-lactamases and mobile elements of clinical *Providencia* isolates from a catheter tip of a patient in Lagos \[[@ref19]\]. To the best of our knowledge, this is the first report of VEB-1 and OXA-10 in clinical isolates of *E. coli, Klebsiella* species, and *P. aeruginosa* from Nigeria. OXA-10 is an important serine β-lactamase because it is inhibited only weakly by clavulanic acid. Interestingly, the risk of widespread ESBL-producing strains among uropathogens not only rendered oxyimino-cephalosporins ineffective but also pose a therapeutic challenge since they are frequently resistant to other kinds of antimicrobial drugs, including aminoglycosides, quinolones, and co-trimoxazole \[[@ref20]\]. There is no association between ESBL genes in the isolates and the various hospitals suggesting that the resistance genes spread across without any peculiar determinant and the RAPD typing found no major clonal or epidemiological relationship which suggested the occurrence and dissemination of a plasmid *bla*~ESBL~.

It is common knowledge that production of ESBLs is the most common mechanism of resistance to third-generation cephalosporins among *Enterobacteriaceae* including *K. pneumoniae* and *E. coli* and mediates multidrug resistance as shown in this study. There is high-level resistance to various other antibiotics including the unprecedented high-level resistance to tigecycline and the level of resistance to colistin and meropenem, a last resort carbapenem antibiotic against GNB. These findings have significant implications for the management of patients with urinary tract infections using third-generation cephalosporins or fluroquinolones, including carbapenems. Carbapenem resistance development in isolates producing CTX-M and other ESBLs due to selection of mutants lacking expression of outer membrane porins has been reported \[[@ref21], [@ref22]\]. Resistance of UTI pathogens to the panels of antibiotics may not be unconnected with their frequent prescription in the hospital, their easy availability in the community without prescription, and their relative affordability which make them subject to abuse.

Conclusions {#sec1-5}
===========

The high-level multidrug resistance of uropathogens to third-generation cephalosporins including other antibiotics used in this study is strongly associated with carriage of ESBLs found in this study, predominantly CTX-M-15, as well as CTX-M-14, OXA-10, and VEB-1. A combination therapy is recommended for use guided by antimicrobial susceptibility testing, and we should furthermore exercise restraint in using or prescribing carbapenems or colistin to prevent selection of resistant isolates.
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###### 

Primer used for the amplification of β-lactamase genes

  Forward primer   Sequence (5′-3′)          Reverse primer   Sequence (3′-5′)              Annealing temp. (°C)   Product size (bp)
  ---------------- ------------------------- ---------------- ----------------------------- ---------------------- -------------------
  CTX-M-1          GACGATGTCACTGGCTGAGC      CTX-M-1          AGCCGCCGACGCTAATACA           60                     499
  CTX-M-9          GCTGGAGAAAAGCAGCGGAG      CTX-M-9          GTAAGCTGACGCAACGTCTG          60                     293
  SHV              AGGATTGACTGCCTTTTTG       SHV              ATTTGCTGATTTCGCTCG            56                     393
  OXA              ATATCTCTACTGTTGCATCTCC    OXA              AAACCCTTCAAACCATCC            50                     216
  OXA-10           GTCTTTCGAGTACGGCATTA      OXA-10           ATTTTCTTAGCGGCAACTTAC         52                     600
  OXA-48           TTCGGCCACGGAGCAAATCAG     OXA-48           GATGTGGGCATATCCATATTCATCGCA   56                     240
  PER-1            ATGAATGTCATTATAAAAGC      PER-1            AATTTGGGCTTAGGGCAGAA          51                     590
  VEB              CGACTTCCATTTCCCGATGC      VEB              GGACTCTGCACCAAATACGC          55                     604
  KPC              ATGTCACTGTATCGCCGTCT      KPC              TAGACGGCCAACACAATAGG          56                     785
  NDM              TTGATGCTGAGCGGGTG         NDM              CTGTCCTTGATCAGGCAGC           56                     578
  VIM              AGTGGTGAGTATCCGACAG       VIM              ATGAAAGTGCGTGGAGAC            56                     261
  GES              CGGTTTCTAGCATCGGGACACAT   GES              CCGCCATAGAGGACTTTAGCACAG      58                     263

###### 

Summary of antimicrobial disk susceptibility testing of 50 bacterial isolates

  Antibiotics (μg/ml)      Sensitive   Intermediate   Resistance
  ------------------------ ----------- -------------- ------------
  Imipenem (10)            36(72)      4(8)           10(20)
  Meropenem (10)           21(42)      12(24)         17(34)
  Amoxycillin-clavulanic   9(18)       5(10)          37(74)
  acid (30)                                           
  Ceftazidime (30)         15(30)      5(10)          30(60)
  Cefotaxime (30)          10(20)      3(6)           37(74)
  Cefpodoxime (10)         11(22)      2(4)           37(74)
  Ceftriaxone (30)         16(32)      2(4)           32(64)
  Nalidixic acid (30)      8(16)       2(4)           40(80)
  Ciprofloxacin (5)        1(2)        7(14)          42(84)
  Chloramphenicol          19(38)      1(2)           30(60)
  Colistin                 38(78)      0 (0)          11(22)
  Sulfonamide              6(12)       1(2)           43(86)
  Tigecycline              0 (0)       3(6)           47(94)

Numbers in parentheses are percentages

###### 

Minimum inhibitory concentrations (MICs) of the 50 bacterial isolates

  Isolate, n                     Antimicrobial agents          MIC (0.06--128 μg/ml)   Sensitive   Intermediate   Resistant   
  ------------------------------ ----------------------------- ----------------------- ----------- -------------- ----------- -----------
  *Escherichia coli*, 19         Ceftriaxone                   \>128                   \>128       0 (0.00)       1 (5.2)     18 (94.7)
                                 Ceftazidime                   \>128                   \>128       0 (0.00)       3 (15.7)    15 (78.9)
                                 Amoxycillin-clavulanic acid   \>128                   \>128       0 (0.00)       0 (0.00)    19(100)
  *Klebsiella pneumoniae*, 21    Ceftriaxone                   \>128                   \>128       1 (4.8)        0 (0.00)    20 (95.0)
                                 Ceftazidime                   \>128                   \>128       0 (0.00)       0 (0.00)    21(100)
                                 Amoxycillin-clavulanic acid   \>128                   \>128       0 (0.00)       0 (0.00)    21(100)
  *Pseudomonas aeruginosa*, 10   Ceftriaxone                   \>128                   \>128       0 (0.00)       0 (0.00)    10(100)
                                 Ceftazidime                   \>128                   \>128       0 (0.00)       0 (0.00)    10(100)
                                 Amoxycillin-clavulanic acid   \>128                   \>128       0 (0.00)       0 (0.00)    10(100)

Numbers in parentheses are percentages

###### 

Carriage of β-lactamase genes and their minimum inhibitory concentrations

  ID no.   Clinical diagnosis            Isolate           MIC (μg/ml)   ESBL phenotype (DDST)   ESBLs genes        
  -------- ----------------------------- ----------------- ------------- ----------------------- ------------- ---- ---------------------------------------------
  AR7      UTI in pregnancy              *E. coli*         \>128         \>128                   \>128         \-   CTX-M-15, OXA
  AR8      UTI                           *E. coli*         \>128         \>128                   \>128         \-   OXA
  AR11     Pelvic inflammatory disease   *E. coli*         128           \>128                   \>128         \-   OXA
  AR12     Prostate enlargement          *E. coli*         \>128         \>128                   \>128         \-   CTX-M-15, CTX-M-14
  AR20     UTI                           *E. coli*         \>128         \>128                   \>128         \+   CTX-M-15, CTX-M-14, SHV, OXA, OXA-10, VEB-1
  AR28     Cystitis                      *E. coli*         \>128         \>128                   \>128         \+   CTX-M-15, SHV, VEB-1, OXA
  AR31     Prostatitis                   *E. coli*         16            128                     \>128         \+   CTX-M-15, CTX-M-9, SHV, OXA and OXA-10
  AR33     Pelvic inflammatory disease   *E. coli*         8             8                       \>128         \-   OXA, SHV and OXA-10
  AR51     UTI                           *E. coli*         \>128         \>128                   \>128         \+   CTX-M-15
  AR65     UTI                           *E. coli*         \>128         \>128                   \>128         \+   CTX-M-15, CTX-M-14, OXA and OXA-10
  AR73     Urosepsis                     *E. coli*         64            \>128                   \>128         \+   CTX-M-15, SHV
  AR2      Prostatitis                   *K. pneumoniae*   32            \>128                   \>128         \-   CTX-M-15, SHV, OXA
  AR16     Chronic kidney disease        *K. pneumoniae*   \>128         \>128                   \>128         \-   CTX-M-15, SHV, OXA
  AR17     Burn injury                   *K. pneumoniae*   \>128         \>128                   \>128         \-   SHV, OXA
  AR18     UTI                           *K. pneumoniae*   \>128         \>128                   \>128         \+   CTX-M-15, CTX-M-14, SHV, OXA, OXA-10, VEB-1
  AR23     UTI                           *K. pneumoniae*   \>128         \>128                   \>128         \-   CTX-M-15, SHV, OXA
  AR32     Glomerulonephritis            *K. pneumoniae*   128           \>128                   \>128         \-   CTX-M-15
  AR54     Prostate enlargement          *K. pneumoniae*   \>128         \>128                   \>128         \+   CTX-M-15, CTX-M-14, SHV, OXA
  AR55     Urosepsis                     *K. pneumoniae*   \>128         \>128                   \>128         \+   CTX-M-15, CTX-M-14, SHV, OXA, OXA-10, VEB-1
  AR71     Prostatitis                   *K. pneumoniae*   \>128         \>128                   \>128         \-   CTX-M-15, CTX-M-14
  AR78     Pelvic inflammatory disease   *K. pneumoniae*   128           \>128                   \>128         \+   CTX-M-15, CTX-M-14
  AR79     UTI                           *K. pneumoniae*   32            \>128                   \>128         \+   CTX-M-15, SHV-
  AR26     Pyelonephritis                *P. aeruginosa*   \>128         \>128                   \>128         \+   CTX-M-15, SHV, OXA and VEB-1
  AR68     Pyelonephritis                *P. aeruginosa*   \>128         \>128                   \>128         \+   CTX-M-15, OXA, OXA-10, VEB-1

CTX-M-1, cefotaximase-Munich-1; OXA, oxacillinase; VEB, Vietnamese extended β-lactamase; MIC, minimum inhibitory concentration; EC, *Escherichia coli;* KP, *Klebsiella pneumoniae;* PA, *Pseudomonas aeruginosa;* DDST, double disc synergyst; +, positive; --, negative
